Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 41.97
OGXI's Cash to Debt is ranked lower than
52% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. OGXI: 41.97 )
Ranked among companies with meaningful Cash to Debt only.
OGXI' s 10-Year Cash to Debt Range
Min: 0.05  Med: 30.59 Max: No Debt
Current: 41.97
Equity to Asset 0.45
OGXI's Equity to Asset is ranked lower than
75% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OGXI: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
OGXI' s 10-Year Equity to Asset Range
Min: -5.36  Med: 0.60 Max: 0.95
Current: 0.45
-5.36
0.95
F-Score: 2
Z-Score: -2.73
M-Score: -6.15
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -154.47
OGXI's Operating margin (%) is ranked lower than
58% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. OGXI: -154.47 )
Ranked among companies with meaningful Operating margin (%) only.
OGXI' s 10-Year Operating margin (%) Range
Min: -48696  Med: -114.25 Max: 9.64
Current: -154.47
-48696
9.64
Net-margin (%) -133.18
OGXI's Net-margin (%) is ranked lower than
57% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. OGXI: -133.18 )
Ranked among companies with meaningful Net-margin (%) only.
OGXI' s 10-Year Net-margin (%) Range
Min: -46544  Med: -105.09 Max: 10.24
Current: -133.18
-46544
10.24
ROE (%) -67.00
OGXI's ROE (%) is ranked lower than
70% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. OGXI: -67.00 )
Ranked among companies with meaningful ROE (%) only.
OGXI' s 10-Year ROE (%) Range
Min: -85.95  Med: -39.12 Max: 12.27
Current: -67
-85.95
12.27
ROA (%) -37.92
OGXI's ROA (%) is ranked lower than
60% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. OGXI: -37.92 )
Ranked among companies with meaningful ROA (%) only.
OGXI' s 10-Year ROA (%) Range
Min: -74.08  Med: -22.97 Max: 7.33
Current: -37.92
-74.08
7.33
ROC (Joel Greenblatt) (%) -7017.48
OGXI's ROC (Joel Greenblatt) (%) is ranked lower than
83% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. OGXI: -7017.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OGXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18547.17  Med: -1074.27 Max: 168.19
Current: -7017.48
-18547.17
168.19
Revenue Growth (3Y)(%) 38.90
OGXI's Revenue Growth (3Y)(%) is ranked higher than
87% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. OGXI: 38.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OGXI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -30.50 Max: 628.7
Current: 38.9
0
628.7
EBITDA Growth (3Y)(%) -10.80
OGXI's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. OGXI: -10.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OGXI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -74.3  Med: -0.10 Max: 104.5
Current: -10.8
-74.3
104.5
EPS Growth (3Y)(%) -1.30
OGXI's EPS Growth (3Y)(%) is ranked higher than
56% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. OGXI: -1.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OGXI' s 10-Year EPS Growth (3Y)(%) Range
Min: -74.7  Med: -1.30 Max: 96.2
Current: -1.3
-74.7
96.2
» OGXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

OGXI Guru Trades in Q3 2014

George Soros Sold Out
First Eagle Investment 515,512 sh (-10.30%)
Jim Simons 236,415 sh (-15.54%)
» More
Q4 2014

OGXI Guru Trades in Q4 2014

Jim Simons 385,483 sh (+63.05%)
First Eagle Investment 515,512 sh (unchged)
» More
Q1 2015

OGXI Guru Trades in Q1 2015

Jim Simons 630,391 sh (+63.53%)
First Eagle Investment Sold Out
» More
Q2 2015

OGXI Guru Trades in Q2 2015

Jim Simons 837,023 sh (+32.78%)
» More
» Details

Insider Trades

Latest Guru Trades with OGXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.33
OGXI's P/B is ranked higher than
73% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. OGXI: 2.33 )
Ranked among companies with meaningful P/B only.
OGXI' s 10-Year P/B Range
Min: 0.3  Med: 2.92 Max: 9
Current: 2.33
0.3
9
P/S 3.72
OGXI's P/S is ranked higher than
77% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. OGXI: 3.72 )
Ranked among companies with meaningful P/S only.
OGXI' s 10-Year P/S Range
Min: 0.59  Med: 5.34 Max: 47.95
Current: 3.72
0.59
47.95
Current Ratio 1.79
OGXI's Current Ratio is ranked lower than
76% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. OGXI: 1.79 )
Ranked among companies with meaningful Current Ratio only.
OGXI' s 10-Year Current Ratio Range
Min: 0.05  Med: 3.56 Max: 18.91
Current: 1.79
0.05
18.91
Quick Ratio 1.79
OGXI's Quick Ratio is ranked lower than
72% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. OGXI: 1.79 )
Ranked among companies with meaningful Quick Ratio only.
OGXI' s 10-Year Quick Ratio Range
Min: 0.05  Med: 3.56 Max: 18.91
Current: 1.79
0.05
18.91
Days Sales Outstanding 3.43
OGXI's Days Sales Outstanding is ranked higher than
95% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. OGXI: 3.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
OGXI' s 10-Year Days Sales Outstanding Range
Min: 8.27  Med: 44.43 Max: 312.07
Current: 3.43
8.27
312.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.62
OGXI's Price/Net Cash is ranked higher than
86% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. OGXI: 2.62 )
Ranked among companies with meaningful Price/Net Cash only.
OGXI' s 10-Year Price/Net Cash Range
Min: 0.59  Med: 4.02 Max: 847.67
Current: 2.62
0.59
847.67
Price/Net Current Asset Value 2.37
OGXI's Price/Net Current Asset Value is ranked higher than
86% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. OGXI: 2.37 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OGXI' s 10-Year Price/Net Current Asset Value Range
Min: 0.49  Med: 4.22 Max: 37.72
Current: 2.37
0.49
37.72
Price/Tangible Book 2.33
OGXI's Price/Tangible Book is ranked higher than
78% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. OGXI: 2.33 )
Ranked among companies with meaningful Price/Tangible Book only.
OGXI' s 10-Year Price/Tangible Book Range
Min: 0.47  Med: 3.94 Max: 30.82
Current: 2.33
0.47
30.82
Price/Median PS Value 0.70
OGXI's Price/Median PS Value is ranked higher than
74% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. OGXI: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
OGXI' s 10-Year Price/Median PS Value Range
Min: 0.15  Med: 1.82 Max: 571.49
Current: 0.7
0.15
571.49
Earnings Yield (Greenblatt) (%) -123.50
OGXI's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. OGXI: -123.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OGXI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 6.4  Med: 112.25 Max: 1723.7
Current: -123.5
6.4
1723.7

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 21
EPS($) -1.60 -1.99
EPS without NRI($) -1.60 -1.99

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SP4A.Germany,
OncoGenex Pharmaceuticals Inc was incorporated in California in October 1991 and reorganized as a Delaware corporation in March 1995. The Company is a biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company has developed a pipeline of late-stage product candidates that are designed to block the production of specific proteins that promote treatment resistance in cancer. The Company has three product candidates in pipeline including custirsen, apatorsen and OGX-225, each of which has a distinct mechanism of action and represents a opportunity for cancer drug development. Of the product candidates in pipeline, custirsen and apatorsen are clinical-stage assets being evaluated in two phase 3 studies and five phase 2 studies. The Company's product candidate's custirsen, apatorsen and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments. Custirsen is currently being evaluated in two phase 3 trials; one in patients with prostate cancer and one in patients with non-small cell lung cancer, or NSCLC. Custirsen is designed to inhibit the production of clusterin, a protein that promotes survival of cancer cells when overexpressed in a variety of tumors. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27, or Hsp27, a cell-survival protein expressed in many types of cancers including bladder, non-small cell lung, pancreatic, prostate and breast cancers. OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that affect the growth of cancer cells when overexpressed. The Company faces competition from pharmaceutical, biopharmaceutical and biotechnology companies that are researching and marketing products designed to address cancer indications. The Company owns trademarks registered in the United States, namely word marks ONCOGENEX, ORCA, Spruce, and Rainier, and design marks ORCA, Cedar, Pacific, Borealis-1, Borealis-2, and the helical totem element that accompanies the clinical trial trademarked identifiers. The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country.
» More Articles for OGXI

Headlines

Articles On GuruFocus.com
George Soros Had A Mixed Day On The Market Oct 30 2014 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 1 Jan 06 2011 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Dec 03 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 17 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 02 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 05 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q/A) May 10 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) May 06 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Nov 05 2009 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
ONCOGENEX PHARMACEUTICALS, INC. Financials Aug 26 2015
10-Q for OncoGenex Pharmaceuticals, Inc. Aug 15 2015
Edited Transcript of OGXI earnings conference call or presentation 13-Aug-15 8:30pm GMT Aug 14 2015
OncoGenex Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Aug 13 2015
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 13 2015
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2015 Aug 13 2015
Q2 2015 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close Aug 13 2015
OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015 Jul 30 2015
OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015 Jul 30 2015
OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015 Jul 30 2015
OncoGenex Pharmaceuticals (OGXI) in Focus: Stock Jumps 5% - Tale of the Tape Jul 27 2015
William Blair Boosts OncoGenex Pharma Target To $6, Hikes Custirsen Probability To 70% Jul 14 2015
OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final... Jul 13 2015
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 13 2015
OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final... Jul 13 2015
OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final... Jul 13 2015
OncoGenex Prostate Cancer Study Adds Co-primary Endpoint - Analyst Blog Jun 11 2015
KB Home Earnings Call scheduled for 12:00 pm ET today Jun 10 2015
FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment Jun 10 2015
FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment Jun 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK